Weekly Recap | Zoetis -2.15%, consensus target above spot
I'm LongbridgeAI, I can summarize articles.The Week
Zoetis (ZTS) fell 2.15% this week to close at $71.40, lagging the S&P 500 by roughly 2.07 percentage points (the S&P 500 was -0.08%). The shares opened Monday (Sep 14) at $74.20, hit a weekly high of $74.82, then drifted lower through the week. Friday (Sep 18) saw the heaviest turnover and a push down to the weekly low of $71.40, where the stock closed. Weekly volume was 26.36m shares, about 0.77% above the 60-day median daily pace. The stock ended in the lower part of its recent range.
Key Events
Company-specific news this week centred on pet-care demand and competitive pressure. On Friday (Sep 18), a report said Zoetis was standing by its guidance even as a weak pet-care market and competition weighed on sales. Earlier in the week, a filing showed Baird Financial Group Inc. had sold some Zoetis shares. A weekend note flagged that Zoetis underperformed rivals on Friday. There were no major product, earnings, or regulatory updates in the week.
Analyst Ratings
Of the 18 brokers covering Zoetis, 5 rate it buy, 4 overweight, and 9 hold, with no underweight or sell ratings. The consensus rating is buy. The consensus target price is $96, about 34.45% above the spot price of $71.40. Broker targets range from $80 to $155, pointing to a fair amount of dispersion. Within the pharmaceutical industry, Zoetis ranks 9th out of 204 names.
The Week Ahead
The macro calendar is busy next week, with the Richmond Fed composite index on Tuesday (Sep 22) and initial jobless claims plus new home sales on Thursday (Sep 24). Zoetis has no earnings event scheduled, so attention stays on pet-care demand and whether the shares can hold the $71-$74 area.
In Short
Zoetis fell this week while the broker consensus stayed at buy and the target price sat above spot, though target dispersion was wide and the latest session showed large-lot money acting as a net seller. Valuation sits around 11.19x P/E and 9.37x book. The key tension is between the still-positive rating posture and the more cautious latest flow signal; the next test is whether pet-care demand stabilises and whether the stock can hold near $71.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.